Hark back: Passive immunotherapy for influenza and other serious infections

Thomas C. Luke, Arturo Casadevall, Stanley Watowich, Stephen L. Hoffman, John H. Beigel, Timothy H. Burgess

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The world is experiencing a pandemic of swine-origin influenza virus H1N1. A vaccine to prevent disease is now available, and millions have or will become ill before they can be vaccinated. The ability to use swine-origin influenza virus vaccines as a public health tool has been described as a "race against time." Oseltamivir and related drugs are being used in an effort to reduce morbidity and mortality, but their efficacy for treating severe influenza is suboptimal, and possible wide-spread emergence of oseltamivir-resistant mutants is a concern. Another approach for prevention and treatment of serious influenza is infusion of hyperimmune plasma. The United States has thousands of licensed blood product collection centers that produce millions of liters of plasma licensed by the Food and Drug Administration on an annual basis for the treatment of serious conditions. Immunotherapy using infusion of convalescent plasma (or hyperimmune intravenous immunoglobulin) has been reported to be an effective treatment for severe influenza and other virulent pathogens in animal models and humans. Plasma obtained from those that have recovered or were early recipients of vaccine offers a resource for production of an immediately available and potentially effective therapy at the local, state, and national level. Past, current, and future uses of immunotherapy and current advisory body recommendations for this approach are presented. Copyrignt

Original languageEnglish (US)
JournalCritical Care Medicine
Volume38
Issue numberSUPPL. 4
DOIs
StatePublished - 2010

Fingerprint

Passive Immunization
Human Influenza
Oseltamivir
Infection
Immunotherapy
Swine
Vaccines
Influenza Vaccines
Intravenous Immunoglobulins
Pandemics
United States Food and Drug Administration
Therapeutics
Orthomyxoviridae
Animal Models
Public Health
Morbidity
Mortality
Pharmaceutical Preparations

Keywords

  • Antibody
  • Convalescent
  • Immunoglobulin
  • Immunotherapy
  • Influenza
  • Passive
  • Plasma
  • Serum

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Hark back : Passive immunotherapy for influenza and other serious infections. / Luke, Thomas C.; Casadevall, Arturo; Watowich, Stanley; Hoffman, Stephen L.; Beigel, John H.; Burgess, Timothy H.

In: Critical Care Medicine, Vol. 38, No. SUPPL. 4, 2010.

Research output: Contribution to journalArticle

Luke, Thomas C. ; Casadevall, Arturo ; Watowich, Stanley ; Hoffman, Stephen L. ; Beigel, John H. ; Burgess, Timothy H. / Hark back : Passive immunotherapy for influenza and other serious infections. In: Critical Care Medicine. 2010 ; Vol. 38, No. SUPPL. 4.
@article{6010b88a648d48489a00ff62f814f12f,
title = "Hark back: Passive immunotherapy for influenza and other serious infections",
abstract = "The world is experiencing a pandemic of swine-origin influenza virus H1N1. A vaccine to prevent disease is now available, and millions have or will become ill before they can be vaccinated. The ability to use swine-origin influenza virus vaccines as a public health tool has been described as a {"}race against time.{"} Oseltamivir and related drugs are being used in an effort to reduce morbidity and mortality, but their efficacy for treating severe influenza is suboptimal, and possible wide-spread emergence of oseltamivir-resistant mutants is a concern. Another approach for prevention and treatment of serious influenza is infusion of hyperimmune plasma. The United States has thousands of licensed blood product collection centers that produce millions of liters of plasma licensed by the Food and Drug Administration on an annual basis for the treatment of serious conditions. Immunotherapy using infusion of convalescent plasma (or hyperimmune intravenous immunoglobulin) has been reported to be an effective treatment for severe influenza and other virulent pathogens in animal models and humans. Plasma obtained from those that have recovered or were early recipients of vaccine offers a resource for production of an immediately available and potentially effective therapy at the local, state, and national level. Past, current, and future uses of immunotherapy and current advisory body recommendations for this approach are presented. Copyrignt",
keywords = "Antibody, Convalescent, Immunoglobulin, Immunotherapy, Influenza, Passive, Plasma, Serum",
author = "Luke, {Thomas C.} and Arturo Casadevall and Stanley Watowich and Hoffman, {Stephen L.} and Beigel, {John H.} and Burgess, {Timothy H.}",
year = "2010",
doi = "10.1097/CCM.0b013e3181d44c1e",
language = "English (US)",
volume = "38",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Hark back

T2 - Passive immunotherapy for influenza and other serious infections

AU - Luke, Thomas C.

AU - Casadevall, Arturo

AU - Watowich, Stanley

AU - Hoffman, Stephen L.

AU - Beigel, John H.

AU - Burgess, Timothy H.

PY - 2010

Y1 - 2010

N2 - The world is experiencing a pandemic of swine-origin influenza virus H1N1. A vaccine to prevent disease is now available, and millions have or will become ill before they can be vaccinated. The ability to use swine-origin influenza virus vaccines as a public health tool has been described as a "race against time." Oseltamivir and related drugs are being used in an effort to reduce morbidity and mortality, but their efficacy for treating severe influenza is suboptimal, and possible wide-spread emergence of oseltamivir-resistant mutants is a concern. Another approach for prevention and treatment of serious influenza is infusion of hyperimmune plasma. The United States has thousands of licensed blood product collection centers that produce millions of liters of plasma licensed by the Food and Drug Administration on an annual basis for the treatment of serious conditions. Immunotherapy using infusion of convalescent plasma (or hyperimmune intravenous immunoglobulin) has been reported to be an effective treatment for severe influenza and other virulent pathogens in animal models and humans. Plasma obtained from those that have recovered or were early recipients of vaccine offers a resource for production of an immediately available and potentially effective therapy at the local, state, and national level. Past, current, and future uses of immunotherapy and current advisory body recommendations for this approach are presented. Copyrignt

AB - The world is experiencing a pandemic of swine-origin influenza virus H1N1. A vaccine to prevent disease is now available, and millions have or will become ill before they can be vaccinated. The ability to use swine-origin influenza virus vaccines as a public health tool has been described as a "race against time." Oseltamivir and related drugs are being used in an effort to reduce morbidity and mortality, but their efficacy for treating severe influenza is suboptimal, and possible wide-spread emergence of oseltamivir-resistant mutants is a concern. Another approach for prevention and treatment of serious influenza is infusion of hyperimmune plasma. The United States has thousands of licensed blood product collection centers that produce millions of liters of plasma licensed by the Food and Drug Administration on an annual basis for the treatment of serious conditions. Immunotherapy using infusion of convalescent plasma (or hyperimmune intravenous immunoglobulin) has been reported to be an effective treatment for severe influenza and other virulent pathogens in animal models and humans. Plasma obtained from those that have recovered or were early recipients of vaccine offers a resource for production of an immediately available and potentially effective therapy at the local, state, and national level. Past, current, and future uses of immunotherapy and current advisory body recommendations for this approach are presented. Copyrignt

KW - Antibody

KW - Convalescent

KW - Immunoglobulin

KW - Immunotherapy

KW - Influenza

KW - Passive

KW - Plasma

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=77950219752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950219752&partnerID=8YFLogxK

U2 - 10.1097/CCM.0b013e3181d44c1e

DO - 10.1097/CCM.0b013e3181d44c1e

M3 - Article

C2 - 20154602

AN - SCOPUS:77950219752

VL - 38

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - SUPPL. 4

ER -